30 results
8-K
APGN
Apexigen Inc
23 Aug 23
Completion of Acquisition or Disposition of Assets
9:01am
have been qualified by certain disclosures not reflected in the text of the Merger Agreement and may apply standards of materiality and other
DEFA14A
APGN
Apexigen Inc
16 Aug 23
Additional proxy soliciting materials
8:00am
or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, Apexigen specifically denies all allegations in the demand
8-K
APGN
Apexigen Inc
15 Aug 23
Other Events
4:31pm
of the legal merit, necessity or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, Apexigen specifically denies all
DEFM14A
APGN
Apexigen Inc
30 Jun 23
Proxy related to merger
4:21pm
to any materiality or Apexigen Material Adverse Effect qualifications set forth therein, except for such failures to be true and correct that would … materiality or Pyxis Oncology Material Adverse Effect qualifications set forth therein, except for such failures to be true and correct that would
425
cbnsq0mzr7dtyqux
24 May 23
Business combination disclosure
7:05am
8-K
EX-2.1
prjv4 axsn77
24 May 23
Pyxis Oncology to Acquire Apexigen
7:02am
8-K
zk2 yej9v
24 May 23
Pyxis Oncology to Acquire Apexigen
7:02am
424B3
yg8m3shknzjxabfwzi
6 Jul 22
Prospectus supplement
4:18pm
S-4/A
urlevne ca
23 May 22
Registration of securities issued in business combination transactions (amended)
8:00pm
CORRESP
hblhgcppo22f
23 May 22
Correspondence with SEC
12:00am
S-4
aomqhnceg9cqoo
8 Apr 22
Registration of securities issued in business combination transactions
6:37pm
10-K
hiqic2wb
7 Apr 22
Annual report
5:13pm
425
EX-2.1
9cnxx3w1skw0 bc1bj2b
18 Mar 22
Business combination disclosure
7:13am